Ruffer LLP’s Indivior Pharmaceuticals INDV Stock Holding History

Ruffer LLP’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-90,247	Closed	-$2.76M	–	202
2026 Q1	$2.76M	Buy	+90,247	New	+$2.98M	0.11%	127

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ruffer LLP's INDV Position: Q2 2026 in Review

Ruffer LLP sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 90,247 shares — an estimated $2.76M sold.

Ruffer LLP first reported a position in INDV in Q1 2026 and held it in 1 quarter. The position peaked at $2.76M in Q1 2026. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Ruffer LLP reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Ruffer LLP sold 90,247 Indivior Pharmaceuticals shares in Q2 2026, an estimated $2.76M.
Ruffer LLP first reported a position in Indivior Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Ruffer LLP's Indivior Pharmaceuticals position peaked at $2.76M in Q1 2026.
338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Ruffer LLP's 13F filing for Q2 2026, filed 30 Jul 2026.